Trials / Conditions / Refractory Transformed Non-Hodgkin Lymphoma

Refractory Transformed Non-Hodgkin Lymphoma

9 registered clinical trials studyying Refractory Transformed Non-Hodgkin Lymphoma — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma NCT06536049	Yazeed Sawalha	Phase 1 / Phase 2
Recruiting	Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphom NCT06834373	Mayo Clinic	Phase 2
Recruiting	Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome NCT05873712	Aseel Alsouqi	Phase 2
Active Not Recruiting	Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have R NCT05627245	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Dr NCT03321643	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Exp NCT03277729	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Active Not Recruiting	Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. NCT03150329	City of Hope Medical Center	Phase 1
Active Not Recruiting	R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphom NCT02628405	Academic and Community Cancer Research United	Phase 1 / Phase 2
Terminated	Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL NCT02572453	National Cancer Institute (NCI)	Phase 2